The pill is intended for adults living with obesity, generally meaning a BMI of 30 or above, as well as adults who are overweight with a BMI of 27 or above who also have a weight-related health condition such as type 2 diabetes, raised blood pressure, high cholesterol or obstructive sleep apnoea
Tirzepatide tells a different story
In addition, potential differences in the magnitude or trajectory of weight loss between semaglutide-treated patients and those achieving weight loss through nonpharmacologic approaches could not be quantified within the platform
While liraglutide decreased cumulative food intake, body weight and white adipose depot weights did not differ between treatment or genotype, likely due to the short period of liraglutide treatment (Supplemental Figure 1, AD
The main adverse effects in the semaglutide arm were gastrointestinal (GI) related, which included nausea, vomiting, diarrhea and constipation